JERUSALEM, Nov. 27,
2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
(Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical
company focused on developing inflammation and immunology (I&I)
biological products and providing CDMO services through its Scinai
Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as a member of
the Company's Scientific Advisory Board (SAB). In this capacity, Dr
Sadeh will play a significant role in advancing the clinical
development of Scinai's lead IL-17 program along with other
promising assets in their unique VHH antibody pipeline.
Dr. Sadeh is an accomplished physician-scientist with over 20
years of experience in drug development and clinical research. He
spent the last five years at Bristol-Myers Squibb (BMS), where he
held multiple senior leadership positions, including Senior Vice
President and Global Programs Head for Immunology, Cardiovascular,
and Neuroscience; Immunology Therapeutic Area Head; and China
R&D Head. Throughout his career, he has been responsible for
multiple drug approvals across various fields, including pulmonary,
rheumatology, dermatology, gastroenterology, and neurology. His
most recent achievement is the approval of Sotyktu, a
first-in-class TYK2 inhibitor for the treatment of psoriasis. Prior
to BMS, Dr. Sadeh held senior leadership positions at Sanofi,
AstraZeneca, and Schering-Plough.
Dr. Sadeh earned his MD in Medicine from the Mount Sinai School
of Medicine and an M.Sc. degree in Clinical Research from
Harvard Medical School. He completed
his fellowship in pulmonary and critical care at Harvard Medical School. He began his medical career
as an academic researcher at Brigham and Women's Hospital.
Dr. Jonathan Sadeh commented: "As
a physician, scientist, and drug developer, I am deeply committed
to advancing innovative therapies for patients with significant
unmet medical needs. Scinai's use of VHH antibodies as a bio-better
approach leverages the unique attributes of VHH antibodies to
overcome the shortcomings of other approved biologics. This
presents a unique way to provide patients with treatments that
truly address their conditions in a meaningful way. The opportunity
to collaborate with esteemed institutions like Max Planck and UMG further strengthens my belief
in Scinai's potential. I look forward to contributing to Scinai's
mission and helping establish it as a globally recognized leader in
scientifically driven drug development".
Amir Reichman, CEO of Scinai,
commented: "We are thrilled to welcome Dr. Jonathan Sadeh to our Scientific Advisory Board.
His extensive experience and proven track record in drug
development and clinical research will be invaluable as we continue
to advance our pipeline of innovative I&I biological products.
We look forward to his contributions and insights as we strive to
bring transformative therapies to patients in need."
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a
biopharmaceutical company with two complementary business units,
one focused on in-house development of inflammation and immunology
(I&I) biological therapeutic products beginning with an
innovative, de-risked pipeline of nanosized VHH antibodies
(nanoAbs) targeting diseases with large unmet medical needs, and
the other a boutique CDMO providing biological drug development,
analytical methods development, clinical cGMP manufacturing, and
pre-clinical and clinical trial design and execution services for
early stage biotech drug development projects.
Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, are forward-looking statements.
Examples of such statements include, but are not limited to,
the development of meaningful drugs and the potential of
Scinai's NanoAb program. These forward-looking statements reflect
management's current views with respect to certain current and
future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from
those expected by the management of Scinai Immunotherapeutics Ltd.
Risks and uncertainties include, but are not limited to; the risk
that the Company will otherwise be unable to remain compliant with
the continued listing requirements of Nasdaq; a delay in the
commencement and results of pre-clinical and clinical
studies, including the Phase 1/2a study for psoriasis; the risk of
delay in, Scinai's inability to conduct, or the unsuccessful
results of, its research and development activities, including the
contemplated in-vivo studies and a clinical trial; inability to
develop meaningful drugs; lower than anticipated revenues of
Scinai's CDMO business in 2024 and thereafter; failure to sign
agreements with other potential clients of the CDMO business; the
risk that Scinai will not be successful in expanding its CDMO
business or in-license other NanoAbs; the risk that Scinai may not
be able to secure additional capital on attractive terms, if at
all; the risk that the therapeutic and commercial potential of
NanoAbs will not be met or that Scinai will not be successful in
bringing the NanoAbs towards commercialization; the risk of a delay
in the preclinical and clinical trials data for NanoAbs, if any;
the risk that our business strategy may not be successful; Scinai's
ability to acquire rights to additional product opportunities;
Scinai's ability to enter into collaborations on terms acceptable
to Scinai or at all; timing of receipt of regulatory approval of
Scinai's manufacturing facility in Jerusalem, if at all or when required; the
risk that the manufacturing facility will not be able to be used
for a wide variety of applications and other vaccine and treatment
technologies; and the risk that drug development involves a lengthy
and expensive process with uncertain outcomes. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
Annual Report on Form 20-F filed with the Securities and Exchange
Commission ("SEC") on May 15, 2024,
and the Company's subsequent filings with the SEC. Scinai
undertakes no obligation to revise or update any forward-looking
statement for any reason.
Logo -
https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-jonathan-sadeh-former-senior-vice-president-of-immunology-rd-at-bristol-myers-squibb-joins-scinai-immunotherapeutics-scientific-advisory-board-302317465.html
SOURCE Scinai Immunotherapeutics Ltd.